L04AJ01 • eculizumab • Antineoplastic and immunomodulating agents | Immunosuppressants | Complement inhibitors
Eculizumab is a monoclonal antibody used for the treatment of rare conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It works by inhibiting complement C5, preventing the destruction of blood cells and tissues.
The medication is administered intravenously, as directed by a doctor, and requires careful monitoring for adverse effects.
Side effects may include headache, hypertension, respiratory infections, or injection site reactions. In rare cases, severe infections such as meningitis may occur.
Eculizumab is not recommended for patients with hypersensitivity to this medication or without meningococcal vaccination.
Substance: eculizumab
Date of last drug list: 01-04-2026
Commercial code: W52098001
Concentration: 10mg / ml
Pharmaceutical form: concentrate for solution for infusion
Quantity: 1
Product type: original
Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.